跳至主要内容
临床试验/DRKS00012497
DRKS00012497已完成不适用

Midterm results of directional atherectomy for treatment of atherosclerotic common femoral artery lesions

niversitäts-Herzzentrum Freiburg-Bad Krozingen0 个研究点目标入组 286 人开始时间: 2017年5月31日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
286

研究概览

简要总结

This analysis included 250 patients. The mean follow-up period was 31.03±21.56 months (range 1-88, median follow-up period 25 months). The procedural complication rate including access-site complications, target lesion perforation, and outflow embolisation was 10.4% (n=26). All but one complication could be treated conservatively or endovascularly. One surgical revision was necessary. Freedom from major adverse events (death, cdTLR, myocardial infarction and major target limb amputation) at 30 days was 99.6%. The rate of cdTLR during follow-up was 13.6% (n=34). A significant improvement of the mean ABI and the RBC was observed. Multivariate logistic regression analysis revealed residual target lesion stenosis >30% (p=0.005), and heavy calcification of the target lesion (p=0.033) to be independent predictors for cdTLR.

研究设计

研究类型
Observational

入排标准

年龄范围
one 至 one(—)
性别
All

入选标准

  • Patients who were treated with atherectomy in the common femoral artery in January 2009-January 2017 and fulfilled the following criteria:
  • Clinical relevant claudication according to Rutherford-Becker classification in the stadium 2 to 5 or to the Fontaine classification in the stadium of IIa to V.
  • Angiography: Arteriosclerotic stenosis (> 70% diameter reduction) or obstruction of the common femoral artery

排除标准

  • no atherectomy in the common femoral artery

研究者

发起方
niversitäts-Herzzentrum Freiburg-Bad Krozingen

相似试验